Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment
2020/08/25 by John M. Dennis, John Dennis · 31 citations
Medicine · Mathematics · #Diabetes Treatment and Management #Statistical Methods in Clinical Trials #Diabetes Management and Research
paper · pdf · doi:10.2337/dbi20-0002
Abstract
Despite the known heterogeneity of type 2 diabetes and variable response to glucose lowering medications, current evidence on optimal treatment is predominantly based on average effects in clinical trials rather than individual-level characteristics. A precision medicine approach based on treatment response would aim to improve on this by identifying predictors of differential drug response for people based on their characteristics and then using this information to select optimal treatment. Recent research has demonstrated robust and clinically relevant differential drug response with all noninsulin treatments after metformin (sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) using routinely available clinical features. This Perspective reviews this current evidence and discusses how differences in drug response could inform selection of optimal type 2 diabetes treatment in the near future. It presents a novel framework for developing and testing precision medicine-based strategies to optimize treatment, harnessing existing routine clinical and trial data sources. This framework was recently applied to demonstrate that "subtype" approaches, in which people are classified into subgroups based on features reflecting underlying pathophysiology, are likely to have less clinical utility compared with approaches that combine the same features as continuous measures in probabilistic "individualized prediction" models.
Citations
Cited by
- A novel diabetes typology: towards precision diabetology from pathogenesis to treatment
- Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
- Recognising, quantifying and accounting for classification uncertainty in type 2 diabetes subtypes
- Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time
- How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials
- Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches
- TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol. [europepmc]
- Screening for regenerative therapy responders in heart failure. [europepmc]
- Genetics of Type 2 Diabetes: Opportunities for Precision Medicine: JACC Focus Seminar. [europepmc]
- Metformin Use and Cognitive Function in Older Adults With Type 2 Diabetes Following a Mediterranean Diet Intervention. [europepmc]
- A novel diabetes typology: towards precision diabetology from pathogenesis to treatment. [europepmc]
- Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. [europepmc]
- Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. [europepmc]
- Personalised Dosing Using the CURATE.AI Algorithm: Protocol for a Feasibility Study in Patients with Hypertension and Type II Diabetes Mellitus. [europepmc]
- Genetics of Type 2 Diabetes: Past, Present, and Future. [europepmc]
- Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time. [europepmc]
- Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. [europepmc]
- Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study. [europepmc]
- Long-term HbA1c variability and macro-/micro-vascular complications in type 2 diabetes mellitus: a meta-analysis update. [europepmc]
- Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. [europepmc]
- The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR. [europepmc]
- Toward Precision Weight-Loss Dietary Interventions: Findings from the POUNDS Lost Trial. [europepmc]
- Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. [europepmc]
- Diabetes and artificial intelligence beyond the closed loop: a review of the landscape, promise and challenges. [europepmc]
- Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations. [europepmc]
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. [europepmc]
- Dirichlet process mixture models to impute missing predictor data in counterfactual prediction models: an application to predict optimal type 2 diabetes therapy. [europepmc]
- Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. [europepmc]
- Etiologies underlying subtypes of long-standing type 2 diabetes. [europepmc]
- Diabetes and obesity: leveraging heterogeneity for precision medicine. [europepmc]
- Predicting responsiveness to GLP-1 pathway drugs using real-world data. [europepmc]
Related